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Abstract
To investigate the prevalence, the antibiotic resistance pattern and the population structure of Staphylococcus aureus, S. aureus isolates
from the anterior nostrils of patients of general practitioners (GPs) were analysed. Insight into the S. aureus population structure is
essential, as nasal carriers of S. aureus are at increased risk of developing an S. aureus infection. S. aureus was isolated from nasal swabs
from 2691 patients with no sign of an infection collected in 29 GP practices in The Netherlands. The susceptibility pattern for several
classes of antibiotics was determined, as well as the S. aureus genetic background, using spa typing. S. aureus was isolated from 617 of
the 2691 (23%) nasal swabs. The prevalences of resistance to ciproﬂoxacin, co-trimoxazole, fusidic acid, macrolides and mupirocin were
0.2%, 0%, 6%, 5% and 1%, respectively. Half of the isolates were associated with a genetic background common to the major methicil-
lin-resistant S. aureus (MRSA) clones, e.g. clonal complex (CC)1, CC5, CC8, CC22, CC30 and CC45, and the remainder were mainly
associated with CC7, CC12, CC15, CC26, CC51 and CC101. The low prevalences of resistance suggest that, in the Dutch situation,
S. aureus isolates from patients visiting their GP because of complaints not related to infection do not represent a large reservoir of
antibiotic resistance genes. Although no MRSA isolates were found, the genetic background of some of the S. aureus isolates is com-
monly observed among community-associated (CA)-MRSA clones (CC1, CC8 and CC30), and this might suggest that these isolates
have the potential to become CA-MRSA.
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Introduction
Staphylococcus aureus is a potential hospital-associated (HA)
and community-associated (CA) pathogen that can cause a
wide variety of infectious diseases, ranging from minor skin
infections to postoperative wound infections and necrotizing
pneumonia [1]. It has been shown previously that nasal carri-
ers of S. aureus are at increased risk of developing an S. aureus
infection [2]. In addition, it has been shown that S. aureus of
any genotype can become a life-threatening pathogen, but that
some clones are more virulent than others [3].
Methicillin-resistant S. aureus (MRSA) is an increasing
problem worldwide, in the form of both HA-MRSA and
CA-MRSA. In The Netherlands, the prevalence of MRSA in
hospitals has doubled during the last few years, from 1% in
2002 to 2% in 2006 [4]. Furthermore, several studies have
reported the emergence of CA-MRSA in The Netherlands
[5,6]. CA-MRSA can cause necrotizing pneumonia and severe
skin infections in patients not at risk of MRSA acquisition.
CA-MRSA is characterized by the presence of Panton–Valen-
tine leukocidin (PVL), the mobile resistance determinant
staphylococcal cassette chromosome mec (SCCmec) type IV
or V, and a continent-speciﬁc genetic background, i.e. clonal
complex (CC)1, CC8, CC30 or CC80 in Europe [7].
It has previously been hypothesized that MRSA originated
through the transfer of SCCmec from MRSA or methicillin-
resistant coagulase-negative staphylococci to extant methicillin-
susceptible S. aureus (MSSA) lineages, and that the genetic
background of S. aureus determines the stability of the new
MRSA clone [8,9]. However, the origin of CA-MRSA is not
known, i.e. whether SCCmec has been acquired by MSSA in the
community, or whether CA-MRSA is derived from HA-MRSA.
Okuma et al. [10] showed that CA-MRSA represent novel
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acquisitions of SCCmec type IV in the community. However,
Aires de Sousa et al. [11] raised the possibility that some CA-
MRSA clones may originate in hospitals, as several similarities
between CA-MRSA and HA-MRSA isolates were found.
In addition to the increased prevalence of MRSA, there is
a growing concern regarding the prevalence of antibiotic-
resistant microorganisms. Antibiotic use is generally consid-
ered to be the main risk factor for antibiotic resistance.
Therefore, optimal use of antibiotics may contribute to the
control of the problem of antibiotic resistance. Thus, for
optimal use of antibiotics, i.e. the right empirical choice for
the bacterial population, actual data on antibiotic resistance
are essential. However, in The Netherlands, no actual data
concerning antibiotic resistance of S. aureus, the main causa-
tive agent of skin infections, among general practitioner (GP)
patients, are available.
The present study investigated the prevalence of antibiotic
resistance of S. aureus isolates from patients visiting their GP
who had no sign of an infection, with the aim of guiding anti-
biotic prescribing by GPs. Furthermore, the population struc-
ture of the S. aureus isolates was determined using spa typing
to investigate whether the S. aureus isolates had a genetic
background commonly observed among CA-MRSA isolates.
Materials and Methods
Study population
Patients visiting 29 GP practices, distributed among four
regions in The Netherlands, participated in this study. The
majority of these practices participated in the sentinel project
of The Netherlands Institute for Health Services Research.
The number of participating practices per region was as
follows: two from the northern part of The Netherlands
(region I), three from the eastern part (region II), 11 from the
middle (region III), and 13 from the southern part (region IV).
During 2005, from 2691 patients with no sign of an infec-
tion, a nose swab was taken from the anterior nostrils,
including 186 from region I, 296 from region II, 901 from
region III, and 1308 from region IV. Each participating GP
included, at random, 50–100 patients (age >12 years). The
S. aureus prevalence data and the antibiotic susceptibility pat-
terns of the S. aureus strains from his or her patients were
sent to the GP anonymously. This study was approved by
the ethical committee of the University Hospital Maastricht.
Isolation of S. aureus
The nasal swabs were sent to the Department of Medical
Microbiology of the University Hospital Maastricht for
further analyses. The swabs were analysed for the presence
of S. aureus using standard microbiological methods, which
included culture on medium containing colistin and naladixic
acid (BD Diagnostics, Erembodegem-Aalst, Belgium) and
nutrient broth (Oxoid, Badhoevedorp, The Netherlands)
containing 6.5% NaCl, as well as oxacillin resistance screen-
ing agar (Oxoid, The Netherlands), for the isolation of
MRSA. All isolates were identiﬁed as S. aureus by Gram stain,
and catalase and coagulase testing [12].
Antimicrobial susceptibility testing
The susceptibility pattern of the S. aureus isolates was deter-
mined according to CLSI guidelines, using the microbroth
dilution method with Mueller–Hinton II cation-adjusted broth
(Becton Dickinson, Franklin Lakes, NJ, USA), an inoculum of
5 · 105 CFU/mL, and overnight incubation at 37C [13]. The
microtitre plates for the determination of the MIC contained
freeze-dried antibiotics (MCS Diagnostics, Swalmen, The
Netherlands). Susceptibility to the following antimicrobial
agents (range in mg/L) was determined: cefaclor (0.06–128),
cefuroxime (0.06–128), clindamycin (0.03–64), ciproﬂoxacin
(0.25–4), clarithromycin (0.03–64), gentamicin (0.06–64), imi-
penem (0.03–64), linezolid (0.03–64), moxiﬂoxacin (0.12–4),
oxacillin (0.03–64), penicillin (0.004–8), rifampin (0.008–16),
teicoplanin (0.06–128), tetracycline (0.03–64), trimethoprim–
sulphamethoxazole (0.015/0.29–32/680) and vancomycin
(0.06–128). Susceptibility to fusidic acid (100 lg) and mupiro-
cin (10 lg) (Rosco, Taastrup, Denmark) was determined
using the disk diffusion method according to CLSI guidelines
[13]. All isolates resistant to clarithromycin were tested for
inducible clindamycin resistance using the D-test according
to CLSI guidelines [14].
Genotypic determinations
The oxacillin-resistant isolates were analysed for the pres-
ence of the mecA gene, using a real-time PCR assay that was
developed in the Department of Medical Microbiology of the
University Hospital Maastricht. The primers and the TaqMan
probe for the detection of mecA were designed on the basis
of the published sequence (GenBank accession no. X52593)
of the mecA gene [15]. The sequences of the forward
(mecA_FP) and reverse (mecA_RP) primer were
5¢-TGAAGTGGTAAATGGTAATATCGACTTAA-3¢ and 5¢-
TAATTCGAGTGCTACTCTAGCAAAGAA-3¢, respectively
(Sigma Genosys, Haverhill, UK). The sequence of the VIC-
labeled MGB probe (mecA_PR) was 5¢-CAAGCAATAGAAT
CATCAGATAA-3¢ (Applied Biosystems, Nieuwerk a/d IJssel,
The Netherlands). A real-time PCR for the S. aureus-speciﬁc
femA gene served as an internal control [16]. The following
reaction conditions were used in the TaqMan assay: 0.3 lM
femA_FP, 0.3 lM femA_RP, 100 nM femA-PR, 0.6 lM
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mecA_FP, 0.6 lM mecA_RP, 125 mM mecA_PR, 1 · TaqMan
Universal PCR Master Mix and 4 lL of a 0.5 McFarland sus-
pension (1.5 · 108 CFU/mL) in a total volume of reaction
mixture of 50 lL. Ampliﬁcation was performed on the ABI
PRISM 7000 Sequence Detection System, using the following
programme: 2 min at 50C and 10 min at 95C, followed by
42 cycles of 15 s at 95C and 60 s at 60C.
The presence of the IleS-2 gene, coding for high-level mup-
irocin resistance, was investigated by PCR as described previ-
ously [17].
Real-time ampliﬁcation of the spa locus, followed by
sequencing, was performed as described previously [18]. The
spa types were clustered into spa-CCs using the algorithm
based upon repeat pattern (BURP) with the Ridom StaphType
version 1.5 software package (http://www.ridom.de). The
default settings recommended by the manufacturer were used.
As it has been shown that spa typing, together with the
algorithm BURP, yields results that are in concordance with
typing results obtained by multilocus sequence typing (MLST)
and pulsed-ﬁeld gel electrophoresis [18,19], the associated
CCs, as determined with MLST, were allocated through the
Ridom SpaServer (http://spaserver.ridom.de).
The presence of PVL was investigated on a random subset
of 100 isolates with a diverse genetic background, using real-
time PCR [20].
Statistical analyses
Signiﬁcant statistical differences were calculated using the
Mann–Whitney U-test, using SPSS 14.0 (SPSS Inc., Gorinchem,
The Netherlands). A p-value of <0.05 was considered to be
statistically signiﬁcant.
Results
Antibiotic susceptibility pattern
S. aureus was isolated from 617 of the 2691 nose swabs
received, resulting in a prevalence of 23%. Only one sample
from each patient was included in the study. Of the 617 iso-
lates, 595 were available for further analyses; the remaining
22 isolates could not be cultured from the frozen stocks. All
isolates were sensitive to clindamycin, trimethroprim–sulpha-
methoxazole and vancomycin. Penicillin resistance was
observed among 68% of the isolates. Resistance to oxacillin
was observed in four isolates. The MIC values were 4 and
8 mg/L for two strains each. None of the 595 S. aureus
strains harboured the mecA gene, and they were therefore
not classiﬁed as MRSA. Resistance to clarithromycin and sus-
ceptibility to clindamycin was observed in 30 isolates (5%).
The D-test showed that 17 of these S. aureus isolates (57%)
had the inducible clindamycin resistance phenotype. Resis-
tance to fusidic acid was observed in 36 isolates (6%), and
2% of the isolates (n = 20) were resistant to tetracycline.
Resistance to mupirocin was observed in two isolates, which
harboured the IleS-2 gene (Table 1).
No statistically signiﬁcant differences (p >0.05) were
observed in the distribution of the resistance patterns in the
four regions.
Distribution of spa types and BURP analyses
The 595 MSSA isolates had 244 different spa types, and BURP
analysis classiﬁed these into 23 spa-CCs (including seven with
no founder) and 46 singletons. Twenty-ﬁve spa types were
excluded from the analysis because the spa region was less
than ﬁve spa repeats in length (Table 2). New spa types were
observed among 48 of the 244 spa types (20%). The most
common spa types observed were t002 (4.1%), t005 (1.7%),
t008 (4.1%), t012 (5.6%), t015 (2.9%), t021 (3.4%), t026 (2.5%),
t056 (1.7%), t084 (3.6%), t091 (5.6%) and t127 (3.6%). Each of
the remaining 233 spa types (61.2% of the isolates) accounted
for between 0.2% and 1.4% each.
The most common spa-CCs were spa-CC 012 (15%),
spa-CC 015 (11%), spa-CC 002 (7%), spa-CC 024 (6%), spa-
CC 127 (5%), spa-CC 005 (3%), spa-CC 122 (2%) and spa-
CC 216 (2%). These spa-CCs were associated with genetic
backgrounds commonly found among endemic MRSA clones,
i.e. CC30, CC45, CC5, CC8, CC1, CC22, CC30 and CC59,
respectively (Table 2). Further major spa-CCs were spa-
CC 084 (14%), spa-CC 078 (5%), spa-CC 166 (4%) and spa-
CC 645/159 (4%). These spa-CCs are associated with CC7/15,
TABLE 1. Antibiotic susceptibility pattern by region
Region Total
No. (%) resistant S. aureus isolates
CIP PEN OXA GEN FAC CLA TET RIF MUP FUC
I 49 (8) 1 (2) 32 (65) 0 (0) 0 (0) 0 (0) 2 (4) 2 (4) 0 (0) 1 (2) 4 (8)
II 50 (8) 0 (0) 35 (70) 1 (2) 0 (0) 0 (0) 1 (2) 2 (4) 1 (2) 0 (0) 4 (8)
III 211 (36) 0 (0) 147 (70) 1 (1) 1 (1) 0 (0) 11 (5) 9 (4) 0 (0) 0 (0) 11 (5)
IV 285 (48) 2 (1) 190 (67) 2 (1) 1 (0) 2 (1) 16 (6) 7 (2) 0 (0) 1 (0) 17 (6)
Total 595 (100) 3 (1) 404 (68) 4 (1) 2 (0) 2 (0) 30 (5) 20 (3) 1 (0) 2 (0) 36 (6)
All isolates were sensitive to cefuroxime, clindamycin, imipenem, linezolid, moxiﬂoxacin, teicoplanin, trimethroprim–sulphamethoxazole, and vancomycin.
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CC26/101, an unknown CC, and CC51 respectively, usually
observed among MSSA clones. The remaining spa-CCs
accounted for <1% of the MSSA isolates (Table 2). The four
borderline oxacillin-resistant S. aureus (BORSA) isolates were
associated with MLST CC1, CC5, CC12 and CC97.
No statistically signiﬁcant differences (p >0.05) were
observed in the distribution of the spa-CCs in the four
regions (Table 3).
Prevalence of PVL
None of the MSSA isolates tested harboured PVL.
Discussion
The prevalence of nasal colonization with S. aureus in the
Dutch community (23%) was in agreement with the preva-
lence in patients admitted to Dutch hospitals (24.4%) [21].
The results of the present study showed a low prevalence of
resistance among S. aureus isolates cultured from the nose of
patients attending their GP with no sign of an infection. The
highest resistance rate was found for penicillin, i.e. 68%,
which is still relatively low as compared to the resistance
levels found among clinical isolates [1]. The low prevalence
of resistance to the antibiotics commonly used by GPs is in
line with the general observation of low extramural antibiotic
use in The Netherlands [22]. The higher resistance to fusidic
acid in comparison with mupirocin (6% vs. <1%) reﬂects the
higher use of fusidic acid than of mupirocin in cases of pro-
ven or possible staphylococcal infection. The latter com-
pound is indicated for use only in cases of MRSA
colonization. The low rates of resistance to mupirocin and
fusidic acid support the current Dutch GP standard for treat-
ment of skin infections. Fusidic acid is the antibiotic of ﬁrst
choice for skin infections, whereas mupirocin is indicated for
S. aureus infections caused by fusidic-resistant S. aureus
strains. However, the population structure of nasal carriage
isolates and clinical isolates can be different [3]. It has been
shown that resistance genes can be located on mobile
genetic elements in the genome of S. aureus, e.g. transposon
Tn554 carrying the ermA gene. In addition, S. aureus strains
can carry plasmids on which resistance genes are present.
TABLE 2. Composition of the spa-CCs
spa-CC
No. (%) of
isolates
No. (%) of
spa types spa typesa Associated CCb
spa-CC 015 67 (11) 27 (11) t505, t583, t589, t620, t630, t772, t908, t950, t1574, t2135, t2239, t2254, t2539, t2541,
t2544, t2568, t2682
45
spa-CC 012 89 (15) 26 (11) t404, t406, t483, t822, t840, t1130, t1239, t1504, t1932, t2209, t2210, t2489, t2561,
t2566, t2572, t2821
30
spa-CC 084 81 (14) 16 (7) t084, t085, t091, t279, t346, t360, t491, t774, t853, t867, t1363, t1716, t2074, t2543,
t2567, t2616
7/15
spa-CC 078 27 (5) 14 (6) t056, t078, t081, t087, t150, t258, t353, t775, t1102, t1312, t1541, t1671, t1898, t2039 26/101
spa-CC 166 21 (4) 11 (5) t089, t136, t153, t166, t240, t369, t1014, t2038, t2071,t2073, t2854
spa-CC 645/159 15 (3) 9 (4) t159, t171, t272, t284, t408, t645, t659, t738, t2213 51
spa-CC 005 18 (3) 9 (4) t005, t060, t223, t474, t790, t1433, t1629, t2618, t2681 22
spa-CC 002 40 (7) 9 (4) t002, t010, t179, t242, t306, t311, t447, t2212, t2491 5
spa-CC 024 38 (6) 9 (4) t008, t024, t190, t648, t701, t711, t846, t1171, t2041 8
spa-CC 122 13 (2) 7 (3) t019, t122, t138, t2387, t2496, t2540, t2610 30
spa-CC 127 28 (5) 5 (2) t127, t177, t591, t1787, t2500 1
spa-CC 216 11 (2) 4 (2) t172, t216, t2079, t2488 59
spa-CC 189 5 (1) 4 (2) t189, t2569, t2612, t2819 1
spa-CC 359 4 (1) 3 (1) t224, t359, t1236 97
spa-CC 160 7 (1) 3 (1) t160, t213, t771 12
spa-CC 1149 4 (1) 3 (1) t937, t1149, t2077
No founder 17 4 (1) 2 (1) t156, t1702 12
No founder 18 3 (1) 2 (1) t246, t2495
No founder 19 2 (0) 2 (1) t034, t571
No founder 20 3 (1) 2 (1) t148, t2016
No founder 21 2 (0) 2 (1) t186, t729 88
No founder 22 2 (0) 2 (1) t814, t2078
No founder 23 6 (1) 2 (1) t364, t493
Singletons 56 (9) 46 (19) t062, t099, t106, t164, t209, t252, t276, t286, t334, t344, t370, t377, t389, t469, t587,
t631, t878, t884, t1045, t1362, t1406, t1943, t2050, t2070, t2075, t2076, t2080, t2208,
t2479, t2490, t2492, t2494, t2542, t2547, t2548, t2556, t2557, t2558, t2559, t2570,
t2573, t2615, t2617, t2674, t2680, t2820
5/30
Excludedc 44 (7) 25 (10) t026, t059, t233, t287, t362, t386, t502, t524, t535, t643, t808, t1152, t1200, t1209,
t1456, t2176, t2207, t2211, t2246, t2383, t2493, t2571, t2611, t2613, t2614
45
Non-typeable 4 (1)
Novel repeat 1 (0)
Total 595 (100) 244
aNew spa types are underlined.
bCC, clonal complex as determined with multilocus sequence typing.
cspa types smaller than ﬁve spa repeats.
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Both transposons and plasmids are mobile and can thus be
transferred to other S. aureus strains of different lineages,
possibly due to antibiotic pressure [23].
The four isolates for which the MIC of oxacillin was 4 or
8 mg/L, but which did not harbour the mecA gene, were classi-
ﬁed as BORSA [24]. Isolates of this kind have been described
previously in a few reports, mostly in a clinical setting, and the
mechanism of b-lactam resistance is not clear at the moment,
but could involve increased production of b-lactamases [24],
or several amino acid substitutions in penicillin-binding pro-
tein 2 [25]. The presence of BORSA as part of the commensal
nasal ﬂora has, to the best of our knowledge, not been
described previously. The clinical signiﬁcance for the individual
patient, or for the patient population in general, has not been
investigated, and it is not known whether these isolates are
‘precursors’ for MRSA and/or whether these isolates spread
as easily as MRSA. Although the mechanism of resistance of
BORSA and that of MRSA are different, the four BORSA
strains had genetic backgrounds (CC1, CC5, CC12 and CC97)
that have previously been observed among MRSA isolates.
CC1 and CC5 are endemic MRSA lineages [26], whereas spo-
radic MRSA isolates associated with CC12 and CC97, i.e.
ST12-MRSA-IV and ST97-MRSA-IV, have been observed
before [27,28]. Furthermore, it has been suggested previously
that low-level resistance could be the gateway to high-level
resistance [29].
For this study, spa typing, together with BURP analyses,
was used to determine the genetic background of the
S. aureus isolates. Next, the spa typing/BURP data were asso-
ciated with the MLST CC on the SpaServer, as has been
done previously [30–33].
Several spa types correspond to a single sequence type
(ST) as determined with MLST, but they remain within an
assigned clonal cluster. Furthermore, several studies have
shown a good correlation between MLST and spa typing/
BURP [18,19]. A disadvantage of spa typing is that it some-
times lacks discriminatory power, due to the related spa
repeat patterns within different clonal lineages, possibly
caused by recombination events involving the spa locus [18].
However, careful study of the ﬁgures generated by BURP
analyses can resolve this problem [30].
In the present study, 52% of the MSSA isolates that could
be classiﬁed into spa-CCs had a genetic background commonly
observed in either epidemic HA-MRSA clones, i.e. CC5, CC8,
CC22, CC30 and CC45 [26], or CA-MRSA clones, i.e. CC1,
CC8, CC30 and CC59 [7]. This percentage is comparable to
that found in a recent study in Belgium, in which 45% of the
MSSA isolates had a genetic background common to the major
MRSA clones [34]. MSSA isolates with a CC1, CC5, CC8,
CC30 and CC45 background have been described previously
in Brazil and Germany, in Danish isolates from the 1960s and
1970s, and in the Dutch and English community [35–40].
CC59 is a common genetic background among CA-MRSA iso-
lates in Asian countries, e.g. Singapore and Taiwan, but has also
been observed recently in The Netherlands [7,41–43].
A recent study among children and elderly people in The
Netherlands showed that CC30 and CC45 were the most
prevalent (47.3%) MSSA clones in the Rotterdam area in the
west of The Netherlands [44]. The present study found these
MSSA clones in only 26% of the study population. A reason for
the difference in prevalence could be the population studied,
or the fact that the present study covered GP patients from
throughout The Netherlands. Although an outbreak of the
community-associated ST80-MRSA-IV clone has recently been
described in the north of The Netherlands, no MSSA isolates
with this genetic background were observed in the present
study [6]. The fact that MSSA isolates with a genetic back-
ground common to CA-MRSA clones were found might sug-
gest that these MSSA isolates could be recipients for SCCmec
type IV or V, as these elements are suggested to be highly
mobile [8], as has been shown previously with the S. aureus
CC30 clone. This clone was prevalent in the 1950s as a penicil-
lin-resistant S. aureus clone, but is now re-emerging, both in
the hospital environment as the ST36-MRSA-II clone, and in
the community as the PVL-positive ST30-MRSA-IV clone
[26,45]. The transfer of SCCmec has been shown to occur
TABLE 3. Distribution of the spa-CCs by region
spa-CC
No. of isolates in region
I II III IV
spa-CC 015 5 4 28 30
spa-CC 012 7 13 26 43
spa-CC 084 6 5 29 41
spa-CC 078 1 3 4 19
spa-CC 166 0 2 11 8
spa-CC 645/159 1 1 7 6
spa-CC 005 2 3 8 5
spa-CC 002 3 1 17 19
spa-CC 024 5 2 15 16
spa-CC 122 1 0 5 7
spa-CC 127 0 2 11 15
spa-CC 216 2 1 1 7
spa-CC 189 0 1 3 1
spa-CC 359 1 1 1 1
spa-CC 160 0 0 5 2
spa-CC 1149 1 0 1 2
No founder 17 0 0 0 4
No founder 18 0 1 0 2
No founder 19 0 0 1 1
No founder 20 0 0 3 0
No founder 21 0 0 1 1
No founder 22 0 0 2 0
No founder 23 0 1 1 4
Singletons 6 5 18 27
Excludeda 7 4 11 22
Non-typeable 0 0 2 2
Novel repeat 1 0 0 0
Total 49 50 211 285
CC, clonal complex.
aspa types smaller than ﬁve spa repeats.
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frequently in the global evolution of MRSA [39,46,47]. How-
ever, high-resolution typing using MLST and S. aureus surface
(sas) genes is needed to investigate the possible transfer of
SCCmec into these MSSA lineages [39].
Several S. aureus clones with a genetic background that
differs from the major MRSA clones, e.g. CC7, CC12,
CC15, CC26, CC51, CC97 and CC101, were found. The
observation that more MSSA CCs were found than CCs
from endemic MRSA clones suggests that the MSSA popula-
tion is more heterogeneous. Similar observations have been
made in Belgium, Brazil, Germany and Portugal
[34,37,48,49]. Recently, MSSA isolates of CC7, CC9, CC12,
CC15, CC25, CC51 and CC101 have been observed in Bel-
gium and in the English community, although no MRSA iso-
lates with these genetic backgrounds were found [34,40].
Similarly, in Portugal, MSSA isolates of CC9, CC12, CC15,
CC25 and CC51 have been found in the community and
the hospital environment, whereas no MRSA isolates
grouped into these CCs were observed [48]. The CC51
genetic background has been found among Danish MSSA
isolates from the 1960s, and among Dutch MSSA isolates
observed between 1997 and 2002 in the community [3,36].
These observations support the existence of successful
MSSA lineages, e.g. CC7 and CC15, both in the Dutch com-
munity and beyond. This also suggests that these MSSA lin-
eages, as compared to other lineages, possess characteristics
that favour their persistence in the host, as well as transfer
between hosts. Further research is necessary to investigate
these characteristics.
The absence of PVL-positive isolates is in agreement with
the study of Melles et al., which revealed a low PVL preva-
lence among isolates from nasal carriers (0.6%) and among
blood culture isolates (2.1%). However, a PVL prevalence of
38.9% was observed among S. aureus strains that caused
abscesses and arthritis, which is in agreement with the
involvement of PVL in soft tissue infections [3].
In conclusion, the results suggest that the S. aureus isolates
tested did not comprise a large reservoir of antibiotic resis-
tance genes. As the MSSA isolates observed had a heteroge-
neous genetic background, both common and uncommon to
major MRSA clones, and as SCCmec type IV and V are
mobile, it is likely that new CA-MRSA clones could emerge
in the future.
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